State Street Corp Solid Biosciences Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.43 - $1.24 $316,563 - $912,881	-736,195 Reduced 68.42%	339,742 $209,000
Q1 2022 May 16, 2022	BUY	$0.74 - $1.79 $113,857 - $275,412	153,862 Added 16.69%	1,075,937 $1.29 Million
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.46 $3,902 - $5,680	-2,309 Reduced 0.25%	922,075 $1.61 Million
Q3 2021 Nov 15, 2021	BUY	$2.38 - $3.77 $160,076 - $253,566	67,259 Added 7.85%	924,384 $2.21 Million
Q2 2021 Aug 16, 2021	BUY	$3.49 - $5.51 $1.36 Million - $2.14 Million	388,761 Added 83.0%	857,125 $3.14 Million
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $290,071 - $579,062	54,017 Added 13.04%	468,364 $2.59 Million
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $283,664 - $717,451	92,099 Added 28.58%	414,347 $3.14 Million
Q3 2020 Nov 10, 2020	BUY	$2.02 - $3.08 $2,981 - $4,546	1,476 Added 0.46%	322,248 $654,000
Q2 2020 Aug 14, 2020	SELL	$2.1 - $3.42 $76,654 - $124,836	-36,502 Reduced 10.22%	320,772 $940,000
Q1 2020 May 11, 2020	BUY	$2.31 - $4.43 $825,302 - $1.58 Million	357,274 New	357,274 $854,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $22.7M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.